Patents by Inventor Caroline Hebert

Caroline Hebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040018980
    Abstract: The present invention is directed to novel polypeptides, designated FIZZ, which are secreted low molecular weight molecules showing no significant sequence homology to any known protein, and nucleic acid sequences encoding such proteins. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptide of the present invention fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides of the present invention. Methods of using FIZZ polypeptides to treat various neurotrophin-related conditions are further provided.
    Type: Application
    Filed: June 13, 2003
    Publication date: January 29, 2004
    Applicant: Genentech, Inc.
    Inventors: Austin L. Gurney, Caroline Hebert, William J. Henzel, Rhona Kabakoff, David L. Shelton, Daniel B. Tumas
  • Publication number: 20020192209
    Abstract: The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds.
    Type: Application
    Filed: November 30, 2001
    Publication date: December 19, 2002
    Applicant: GENENTECH, INC.
    Inventors: Kevin P. Baker, Audrey Goddard, Austin L. Gurney, Caroline Hebert, William Henzel, Rhona C. Kabakoff, David L. Shelton, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 5874080
    Abstract: Methods are provided for the treatment of asthma with anti-IL-8 monoclonal antibodies.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: February 23, 1999
    Assignee: Genentech, Inc.
    Inventors: Caroline A. Hebert, Rhona C. Kabakoff, Mark W. Moore
  • Patent number: 5874543
    Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: February 23, 1999
    Assignee: Genetech, Inc.
    Inventors: Anan Chuntharapai, James Lee, Caroline Hebert, K. Jin Kim
  • Patent number: 5840856
    Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: November 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, James Lee, Caroline Hebert, K. Jin Kim
  • Patent number: 5543503
    Abstract: cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: August 6, 1996
    Assignee: Genentech Inc.
    Inventors: Anan Chuntharapai, James Lee, Caroline Hebert, K. Jin Kim
  • Patent number: 5451399
    Abstract: A novel polypeptide [Ala IL-8].sub.77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.
    Type: Grant
    Filed: October 19, 1992
    Date of Patent: September 19, 1995
    Assignees: Brigham and Women's Hospital, Genentech, Inc.
    Inventors: Michael A. Gimbrone, Jr., Martin S. Obin, Joffre B. Baker, Caroline A. Hebert
  • Patent number: 5440021
    Abstract: cDNAs encoding a class of receptors, including the IL-8 type B receptor, have been identified in human tissue. Recombinantly produced IL-8 type B receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: August 8, 1995
    Inventors: Anan Chuntharapai, Caroline Hebert, Kyung J. Kim, James Lee